keyword
MENU ▼
Read by QxMD icon Read
search

Cipn

keyword
https://www.readbyqxmd.com/read/29746899/ncs-1-is-a-regulator-of-calcium-signaling-in-health-and-disease
#1
REVIEW
Göran R Boeckel, Barbara E Ehrlich
Neuronal Calcium Sensor-1 (NCS-1) is a highly conserved calcium binding protein which contributes to the maintenance of intracellular calcium homeostasis and regulation of calcium-dependent signaling pathways. It is involved in a variety of physiological cell functions, including exocytosis, regulation of calcium permeable channels, neuroplasticity and response to neuronal damage. Over the past 30 years, continuing investigation of cellular functions of NCS-1 and associated disease states have highlighted its function in the pathophysiology of several disorders and as a therapeutic target...
May 7, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29735874/-effectiveness-of-non-pharmacologic-interventions-in-chemotherapy-induced-peripheral-neuropathy-a-systematic-review-and-meta-analysis
#2
REVIEW
Pok Ja Oh, You Lim Kim
PURPOSE: This study was conducted to evaluate the effectiveness of non-pharmacologic interventions in chemotherapy-induced peripheral neuropathy (CIPN). METHODS: PubMed, Cochrane Library CENTRAL, EMBASE, CINAHL, and several Korean databases (Until August 2017) were searched. The main search strategy combined terms for peripheral neuropathy and presence of neoplasms. The risk of bias was assessed using the Cochrane's Risk of Bias tool for randomized studies and the Risk of Bias Assessment tool for non-randomized studies...
April 2018: Journal of Korean Academy of Nursing
https://www.readbyqxmd.com/read/29716954/nmnat-mitigates-sensory-dysfunction-in-a-drosophila-model-of-paclitaxel-induced-peripheral-neuropathy
#3
Jennifer M Brazill, Beverley Cruz, Yi Zhu, R Grace Zhai
Chemotherapy-induced peripheral neuropathy (CIPN) is the major dose-limiting side effect of many commonly used chemotherapeutic agents, including paclitaxel. Currently there are no neuroprotective or effective symptomatic treatments for CIPN. Lack of understanding of the in vivo mechanisms of CIPN has greatly impeded the identification of therapeutic targets. Here we optimized a model of paclitaxel-induced peripheral neuropathy using Drosophila larvae that recapitulates aspects of chemotherapy-induced sensory dysfunction ...
April 30, 2018: Disease Models & Mechanisms
https://www.readbyqxmd.com/read/29710662/antinociceptive-effectiveness-of-tithonia-tubaeformis-in-a-vincristine-model-of-chemotherapy-induced-painful-neuropathy-in-mice
#4
Noor Ul Ain Nawaz, Muhammad Saeed, Khalid Rauf, Muhammad Usman, Mehreen Arif, Zaki Ullah, Naila Raziq
BACKGROUND: Chemotherapy induced peripheral neuropathy (CIPN) is a painful side-effect of commonly used chemotherapeutic agents that profoundly impair the quality of life of patients as the current pharmacotherapeutic strategies are inefficient in providing adequate pain relief. Complementary and alternative medicine (CAM) therapies are preferred by patients with neuropathic pain as they experience insufficient control of pain with conventional medications. This study describes the antinociceptive effect of Tithonia tubaeformis (Jacq...
April 25, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29695418/role-of-complement-in-a-rat-model-of-paclitaxel-induced-peripheral-neuropathy
#5
Jijun Xu, Lingjun Zhang, Mian Xie, Yan Li, Ping Huang, Thomas L Saunders, David A Fox, Richard Rosenquist, Feng Lin
Chemotherapy-induced peripheral neuropathy (CIPN) is a painful and debilitating side effect of cancer chemotherapy with an unclear pathogenesis. Consequently, the available therapies for this neuropathic pain syndrome are inadequate, leading to a significantly reduced quality of life in many patients. Complement, a key component of the innate immune system, has been associated with neuroinflammation, a potentially important trigger of some types of neuropathic pain. However, the role of complement in CIPN remains unclear...
April 25, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29680317/a-double-blind-placebo-controlled-phase-ii-randomised-cross-over-trial-investigating-the-use-of-duloxetine-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy
#6
Eva Battaglini, Susanna B Park, Elizabeth H Barnes, David Goldstein
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of cancer treatment, potentially leading to early cessation of chemotherapy, enduring symptoms and long-lasting disability. Evidence from preclinical and clinical studies suggests that duloxetine, a serotonin-noradrenaline reuptake inhibitor, may be effective in the symptomatic treatment of CIPN. This double blind, placebo controlled, phase II randomised cross-over trial aims to determine whether treatment with duloxetine results in a reduction in chronic neuropathic symptoms experienced as a result of neurotoxic chemotherapy treatment...
April 19, 2018: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/29649081/psychometric-testing-of-the-european-organisation-for-research-and-treatment-of-cancer-quality-of-life-questionnaire-chemotherapy-induced-peripheral-neuropathy-20-item-scale-using-pooled-chemotherapy-induced-peripheral-neuropathy-outcome-measures-standardization
#7
Ellen M Lavoie Smith, Tanima Banerjee, James J Yang, Celia M Bridges, Paola Alberti, Jeff A Sloan, Charles Loprinzi
BACKGROUND: No criterion-standard patient-reported outcome measure of chemotherapy-induced peripheral neuropathy (CIPN) exists. OBJECTIVES: The aims of this study were to reevaluate the sensitivity, reliability, and validity of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN (QLQ-CIPN20) measure and suggest possible revisions that could strengthen it. METHODS: Cross-sectional QLQ-CIPN20 data from 8 European countries (n = 271) were pooled with data from 4 North American multisite CIPN intervention trials (n = 884)...
April 12, 2018: Cancer Nursing
https://www.readbyqxmd.com/read/29605500/course-of-chemotherapy-induced-peripheral-neuropathy-and-its-impact-on-health-related-quality-of-life-among-ovarian-cancer-patients-a-longitudinal-study
#8
Cynthia S Bonhof, Floortje Mols, M Caroline Vos, Johanna M A Pijnenborg, Dorry Boll, Gerard Vreugdenhil, Nicole P M Ezendam, Lonneke V van de Poll-Franse
OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) presents itself as sensory peripheral neuropathy (SPN) or motor peripheral neuropathy (MPN). Our aim was to examine the course of SPN and MPN, and their impact on health-related quality of life (HRQoL) among ovarian cancer patients. METHODS: All newly diagnosed ovarian cancer patients from twelve hospitals in the South of the Netherlands were eligible for participation. Patients (N=174) completed questions on CIPN (EORTC QLQ-OV28) and HRQoL (EORTC QLQ-C30) after initial treatment and at 6, 12, and 24months (response rates were 70%, 71%, 58%, and 43% respectively)...
March 28, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29602320/pre-treatment-anxiety-is-associated-with-persistent-chemotherapy-induced-peripheral-neuropathy-in-women-treated-with-neoadjuvant-chemotherapy-for-breast-cancer
#9
Kwang-Min Lee, Dooyoung Jung, Heesung Hwang, Kyung-Lak Son, Tae-Yong Kim, Seock-Ah Im, Kyung-Hun Lee, Bong-Jin Hahm
OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent adverse reaction caused by chemotherapeutic agents, especially the taxanes. CIPN can persist from months to years after completion of chemotherapy, decreasing quality of life for cancer survivors. The aim of this study was to explore the incidence and risk factors of persistent CIPN among women with breast cancer receiving neoadjuvant chemotherapy. METHODS: In this prospective study, we recruited women with breast cancer receiving neoadjuvant chemotherapy, including four cycles of docetaxel...
May 2018: Journal of Psychosomatic Research
https://www.readbyqxmd.com/read/29570617/dietary-intake-of-magnesium-or-calcium-and-chemotherapy-induced-peripheral-neuropathy-in-colorectal-cancer-patients
#10
Evertine Wesselink, Renate M Winkels, Harm van Baar, Anne J M R Geijsen, Moniek van Zutphen, Henk K van Halteren, Bibi M E Hansson, Sandra A Radema, Johannes H W de Wilt, Ellen Kampman, Dieuwertje E G Kok
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe side-effect in colorectal cancer (CRC) patients. This study assessed the association between habitual dietary intake of magnesium or calcium and prevalence and severity of chronic CIPN in CRC patients receiving adjuvant chemotherapy. For this prospective cohort study, 196 CRC patients were considered. Magnesium and calcium intake was determined using a food frequency questionnaire at diagnosis, during and after chemotherapy. Chronic CIPN was assessed 12 months after diagnosis using the quality of life questionnaire CIPN20...
March 23, 2018: Nutrients
https://www.readbyqxmd.com/read/29554018/chemokine-ccl2-and-its-receptor-ccr2-in-the-dorsal-root-ganglion-contribute-to-oxaliplatin-induced-mechanical-hypersensitivity
#11
A M Illias, A C Gist, H Zhang, A K Kosturakis, P M Dougherty
Activation of innate immune mechanisms within the dorsal root ganglion (DRG) and spinal dorsal horn has been shown to play a key role in the development of neuropathic pain including paclitaxel-related chemotherapy-induced peripheral neuropathy (CIPN). Here we tested whether similar mechanisms are generalizable to oxaliplatin-induced CIPN. After a single intraperitoneal injection of 3mg/kg oxaliplatin, mechanical withdrawal threshold and the expression of C-C chemokine ligand 2 (CCL2) and its receptor, CCR2 in the DRG were measured by behavioral testing and immunohistochemical (IHC) staining, respectively...
March 15, 2018: Pain
https://www.readbyqxmd.com/read/29546345/supplement-use-and-chemotherapy-induced-peripheral-neuropathy-in-a-cooperative-group-trial-s0221-the-delcap-study
#12
Gary R Zirpoli, Susan E McCann, Lara E Sucheston-Campbell, Dawn L Hershman, Gregory Ciupak, Warren Davis, Joseph M Unger, Halle C F Moore, James A Stewart, Claudine Isaacs, Timothy J Hobday, Muhammad Salim, Gabriel N Hortobagyi, Julie R Gralow, G Thomas Budd, Kathy S Albain, Christine B Ambrosone
Background: Chemotherapy-induced peripheral neuropathy (CIPN) can interfere with daily function and quality of life, and there are no known preventive approaches. In a cohort of breast cancer patients receiving paclitaxel as part of a clinical trial (SWOG 0221), we examined the use of dietary supplements both before diagnosis and during treatment in relation to CIPN. Methods: At registration to S0221, 1225 breast cancer patients completed questionnaires regarding the use of multivitamins and supplements before and at diagnosis...
December 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29524582/associations-between-perceived-stress-and-chemotherapy-induced-peripheral-neuropathy-and-otoxicity-in-adult-cancer-survivors
#13
Christine Miaskowski, Steven M Paul, Judy Mastick, Gary Abrams, Kimberly Topp, Betty Smoot, Kord M Kober, Margaret Chesney, Melissa Mazor, Grace Mausisa, Mark Schumacher, Yvette P Conley, Jennifer Henderson Sabes, Steven Cheung, Margaret Wallhagen, Jon D Levine
CONTEXT: The most common adverse effects from neurotoxic chemotherapy are chemotherapy-induced neuropathy (CIPN), hearing loss, and tinnitus. Although associations between perceived stress and persistent pain, hearing loss, and tinnitus are documented, no studies have examined these associations in cancer survivors who received neurotoxic chemotherapy. OBJECTIVES: In this cross-sectional study, we evaluated for associations between perceived stress and the occurrence of CIPN, hearing loss, and tinnitus, in 623 adult cancer survivors who received platinum and/or taxane compounds...
March 7, 2018: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/29503217/estimating-the-frequency-severity-and-clustering-of-spade-symptoms-in-chronic-painful-chemotherapy-induced-peripheral-neuropathy
#14
Robert Knoerl, Zach Chornoby, Ellen M L Smith
Patients undergoing treatment for cancer commonly experience symptoms such as sleep disturbance, pain, anxiety, depression, and low energy/fatigue (SPADE), subsequently altering physical function and complicating effective symptom management. However, little is known about the frequency, severity, and clustering of SPADE symptoms in individuals with chronic painful chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this cross-sectional, secondary analysis was to describe the frequency, severity, and clustering of SPADE symptoms and their association with physical function in individuals with chronic painful CIPN...
March 1, 2018: Pain Management Nursing: Official Journal of the American Society of Pain Management Nurses
https://www.readbyqxmd.com/read/29498961/short-term-recovery-of-balance-control-association-with-chemotherapy-induced-peripheral-neuropathy-in-pediatric-oncology
#15
Laura S Gilchrist, Lynn R Tanner
PURPOSE: To describe the incidence and short-term recovery of balance control in children and adolescents receiving neurotoxic treatment for noncentral nervous system cancers and to investigate the association of chemotherapy-induced peripheral neuropathy and balance control. METHODS: Sixty-five children and adolescents diagnosed with leukemia, lymphoma, or other solid tumors were tested 3 to 6 months into treatment and 3 and 6 months following treatment using the Bruininks-Oseretsky Balance Subscale and Pediatric Modified Total Neuropathy Scale scores of chemotherapy-induced peripheral neuropathy (CIPN)...
April 2018: Pediatric Physical Therapy
https://www.readbyqxmd.com/read/29484113/the-prevention-of-chemotherapy-induced-peripheral-neuropathy-by-concurrent-treatment-with-drugs-used-for-bipolar-disease-a-retrospective-chart-analysis-in-human-cancer-patients
#16
Roxanne J Wadia, Marilyn Stolar, Clarice Grens, Barbara E Ehrlich, Herta H Chao
Peripheral neuropathy is a major adverse effect in the use of chemotherapeutic drugs. In nearly 50% of patients, chemotherapy induced peripheral neuropathy (CIPN) has been reported as irreversible. With increasing numbers of patients surviving treatment as well as increasing duration of survival after treatment, reducing the side effects of chemotherapy and improving the quality of life has become a major focus of cancer survivorship. Multiple classes of chemotherapeutic drugs including taxanes, platinum agents and vinka alkaloids list peripheral neuropathy as the main dose-limiting side effect of treatment...
January 26, 2018: Oncotarget
https://www.readbyqxmd.com/read/29480026/in-search-of-a-gold-standard-patient-reported-outcome-measure-for-use-in-chemotherapy-induced-peripheral-neuropathy-clinical-trials
#17
Ellen M Lavoie Smith, Robert Knoerl, James J Yang, Grace Kanzawa-Lee, Deborah Lee, Celia M Bridges
PURPOSE: To test a reduced version-CIPN15-of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy scale (QLQ-CIPN20) to establish a possible gold-standard patient-reported outcome measure for chemotherapy-induced peripheral neuropathy (CIPN). METHODS: Using a prospective, longitudinal, case-control design, patients (n = 121) receiving neurotoxic chemotherapy completed the CIPN15 at baseline and 12 weeks and underwent objective neurological assessment using the 5-item Total Neuropathy Score-Clinical (TNSc)...
January 2018: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/29461625/beyond-symptomatic-relief-for-chemotherapy-induced-peripheral-neuropathy-targeting-the-source
#18
REVIEW
Jiacheng Ma, Annemieke Kavelaars, Patrick M Dougherty, Cobi J Heijnen
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious adverse side effect of many chemotherapeutic agents, affecting >60% of patients with cancer. Moreover, CIPN persists long into survivorship in approximately 20% to 30% of these patients. To the authors' knowledge, no drugs have been approved to date by the US Food and Drug Administration to effectively manage chemotherapy-induced neuropathic pain. The majority of the drugs tested for the management of CIPN aim at symptom relief, including pain and paresthesia, yet are not very efficacious...
February 20, 2018: Cancer
https://www.readbyqxmd.com/read/29439162/incidence-and-disease-burden-of-chemotherapy-induced-peripheral-neuropathy-in-a-population-based-cohort
#19
Arya Shah, E Matthew Hoffman, Michelle L Mauermann, Charles L Loprinzi, Anthony J Windebank, Christopher J Klein, Nathan P Staff
OBJECTIVE: To assess disease burden of chemotherapy-induced peripheral neuropathy (CIPN), which is a common dose-limiting side effect of neurotoxic chemotherapy. Late effects of CIPN may increase with improved cancer survival. METHODS: Olmsted County, Minnesota residents receiving neurotoxic chemotherapy were identified and CIPN was ascertained via text searches of polyneuropathy symptoms in the medical record. Clinical records were queried to collect data on baseline characteristics, risk factors, signs and symptoms of CIPN, medications, impairments and International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes for all subjects...
February 8, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29427084/rosmarinic-acid-mitigates-mitochondrial-dysfunction-and-spinal-glial-activation-in-oxaliplatin-induced-peripheral-neuropathy
#20
Aparna Areti, Prashanth Komirishetty, Anil Kumar Kalvala, Karthika Nellaiappan, Ashutosh Kumar
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting complication which develops as a consequence of treatment with chemotherapeutic agents like oxaliplatin and is a mainstay of therapy for colorectal cancer. Ever since CIPN was identified, understanding its exact pathomechanisms remains a clinical challenge. The role of mitochondrial dysfunction and glial cell activation has surfaced in the etiology of CIPN. Rosmarinic acid (RA), a known mitoprotectant exerts neuroprotection against the oxidative stress and neuroinflammation in various disease conditions...
February 9, 2018: Molecular Neurobiology
keyword
keyword
30770
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"